Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Glucotrack (GCTK) will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery ...

K Street is still digesting the 90-day pause on Trump’s so-called reciprocal tariffs to chart the best path forward for clients over the next three months.

A new agreement with OneTwo Analytics AB will allow Glucotrack to leverage next-generation artificial intelligence and machine learning-based analytics to evaluate clinical study data from its continu ...

Glucotrack, Inc., a medical device company with a market capitalization of $1.78 million, has received a notification from the Nasdaq Stock Market indicating a potential delisting of its securities ...

Glucotrack, Inc., a medical device company with a market capitalization of $1.78 million, has received a notification from the Nasdaq Stock Market indicating a potential delisting of its ...